CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 190 enrolled
Drug / intervention
Empagliflozin 10 MG +1 moredrug
Likely dose
Empagliflozin 10 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03198585
NCT03198585Phase 2Completed
CompareCT.gov

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Morten Schou·interventional·Posted Jun 26, 2017·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating Empagliflozin 10 MG and Placebo for Heart Failure With Reduced Ejection Fraction. Completed, enrolled 190 participants across 2 sites.

Detailed Summary

To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction. The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure With Reduced Ejection Fraction
CountriesDenmark
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 26, 2017
Enrollment StartJun 29, 2017
Primary CompletionDec 20, 2019
Study CompletionJan 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.0 years ago

Interventions

Empagliflozin 10 MGdrug

Capsule, once a day for 90 days

Placeboother

Capsule, once a day for 90 days